Research Paper Volume 11, Issue 2 pp 741—755

Association between antidiabetic agents use and leukocyte telomere shortening rates in patients with type 2 diabetes

class="figure-viewer-img"

Figure 1. Comparison of telomere length and TSR between treated vs untreated T2DM patients. Linear regression analysis of telomere length and age in the treatment group (A) and nontreatment group (B); comparison of telomere length (C) and TSR (D) between the two groups. Solid lines in A and B indicate mean telomere lengths, calculated by regression analyses; y = -14.01*x+6976 in A (r = -0.24, P < 0.0001) and y = -15.74*x+7141 in B (r = -0.27, P < 0.05). y = telomere length in bp and x = age in years. (D) TSR was found to be -14.01 ± 3.28 bp/year in the treatment group (n = 304) and -15.74 ± 6.21 bp/year in the nontreatment group (n = 84). Telomere length is presented as the mean ± SD. TSRs are presented as the mean ± SEM. ns indicates P > 0.05, ***indicates P < 0.001